Eventide Asset Management LLC Has $95.19 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Eventide Asset Management LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 188,412 shares of the company’s stock after acquiring an additional 88 shares during the quarter. IDEXX Laboratories accounts for approximately 1.6% of Eventide Asset Management LLC’s portfolio, making the stock its 13th largest position. Eventide Asset Management LLC’s holdings in IDEXX Laboratories were worth $95,190,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IDXX. Ridgewood Investments LLC acquired a new position in shares of IDEXX Laboratories during the second quarter valued at about $27,000. Institutional & Family Asset Management LLC acquired a new position in IDEXX Laboratories during the 2nd quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after acquiring an additional 57 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after acquiring an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.1 %

Shares of NASDAQ:IDXX opened at $421.76 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a market capitalization of $34.54 billion, a PE ratio of 40.67, a price-to-earnings-growth ratio of 3.68 and a beta of 1.36. The business has a fifty day moving average price of $453.61 and a two-hundred day moving average price of $478.67. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.53 earnings per share. Analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research reports. Piper Sandler reissued a “neutral” rating and issued a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Barclays decreased their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.